Publications & News

Stay Up-To-Date with Prolong

Featured
News
April 30, 2026
Prolong’s Investigational Therapy for Acute Ischemic Stroke, PP-007, Receives FDA Breakthrough Therapy Designation
Latest
News
October 20, 2025
Prolong Pharmaceuticals to Present Phase 1/2 Data from HEMERA-1 for PP-007 in Acute Ischemic Stroke (AIS) at the 2025 World Stroke Conference (WSC)
News
February 5, 2025
Prolong Pharmaceuticals to Present Preliminary Phase 1 Data from HEMERA-1 for PP-007 in Acute Ischemic Stroke (AIS) at the 2025 International Stroke Conference (ISC)
News
November 13, 2024
Prolong Pharmaceuticals to Present Clinical Data regarding PP-007, PEGylated carboxyhemoglobin bovine product, at the 2024 International Symposium on Blood Substitutes (ISBS)
News
October 30, 2024
U.S. Food and Drug Administration (FDA) Grants Prolong Pharmaceuticals FDA Fast Track Designation for Novel Stroke Therapy (PP-007) in HEMERA-1 Clinical Study

All our resources

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

References

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.

Be part of Our journey

Join us in advancing treatments for severe and life-threatening conditions.
call us
or
email our team
Address
300 Corporate Court, Suite B
South Plainfield, NJ 07080 USA
Phone
(908) 444-4660 direct
(908) 444-4661 fax
Email
info@prolongpharma.com
About Us
Meet ProlongManagement TeamMedical Advisory BoardOur Investors
Sanguinate®
PipelineHow it WorksGlobal Strokes FactsClinical Trials
Resources
PublicationsConferencesNewsReferences
Legal
Copyright Notice
Terms & Conditions
Privacy Policy
Expanded Access Policy
Prolong Pharmaceuticals, LLC does not provide any investigational drugs to patients outside of participation in an active clinical trial. For more information on our ongoing clinical trials, please contact info@prolongpharma.com.